Abstract

Aim and Objective: MMP-13 belongs to a large family of proteases called matrix metalloproteinases (MMPs) that degrades type II collagen, the main structural protein of articular cartilage. The main pathologic role of MMP-13 over expression is to contribute to the development of osteoarthritis.

Methods: To find new inhibitors with possible selectivity for MMP-13 a structure based virtual screening was employed. The inhibitory activities of 11 inhibitors among 19 purchased compounds were approved by enzyme inhibition assay.

Results: Our results demonstrated that the CADD (computer aided drug design) could be successfully applied to find new MMP-13 inhibitors using a receptor structure (PDB code: 3O2X) which had been demonstrated a good performance in a cross-docking study.

Conclusion: We discovered inhibitors with new scaffolds for inhibition of MMP-13 and some selectivity features such as proper S1′ occupancy and interactions with S1′ pocket that could be subjected to a future lead optimization study.

Keywords: Computer aided drug design, docking, matrix metalloproteinase, MMP-13, osteoarthritis, virtual screening.